Mitotane
From Wikipedia, the free encyclopedia
![]() |
|
Mitotane
|
|
Systematic (IUPAC) name | |
1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)-ethyl]-benzene | |
Identifiers | |
CAS number | |
ATC code | L01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C14H10Cl4 |
Mol. mass | 320.04 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 6% |
Metabolism | ? |
Half life | 18 to 159 days |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Mitotane is a medication used in the treatment of the rare disease adrenocortical carcinoma.
It has been produced by Bristol Myers Squibb SpA but it is marketed as an orphan drug due to the small number of patients in need of it. Its administration occurs in cases where the tumour cannot be surgically omitted.
Mitotane alternates steroides peripheral metabolism, represses directly the adrenal cortex and alternates cortisone metabolism. It is an isomere chemically to DDT.
Its trade name is Lysodren.
Mitotane is also used to treat pituitary-dependent Cushing's syndrome in canines. The medication is used in the controlled destruction of adrenal tissue, leading to a decrease in cortisol production. [1]